Supported by Oxford University Innovation, the company will leverage over two decades of work by co-founder Professor Paresh Vyas to target common cancer proteins...
A groundbreaking concept combining traditional Chinese medicine (TCM) and modern immunology could revolutionize our approach to treating complex diseases.
Source link